Several well-established oncogenes, including FGFR2, C-MYC, PTGS2 and HIF1A, among others, are TIA-regulated gene targets at the transcriptional and/or posttranscriptional levels.7, 11, 12, 13, 14, 15, 16, 17, 18, 20, 21 Further, TIA1 expression in tumors strongly correlates with responsiveness to immunotherapy in melanoma and sarcoma patients.46, 47, 48, 49. This evidence concerns the gene TIA1 and sarcoma.